FAM
CRDF icon

Fred Alger Management’s Cardiff Oncology CRDF Stock Holding History

Fred Alger Management’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-918
Closed -$671K – 477
2015
Q2 		$671K Buy
+918
New +$651K ﹤0.01% 450

Other funds holding CRDF

BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MWVC
Morgens Waterfall Vintiadis & Co New York $131M AUM 101.21% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Fred Alger Management's CRDF Position: Q3 2015 in Review

Fred Alger Management sold out of Cardiff Oncology (CRDF) in Q3 2015, closing a stake of 918 shares — an estimated $671K sold.

Fred Alger Management first reported a position in CRDF in Q2 2015 and held it in 1 quarter. The position peaked at $671K in Q2 2015. 60 funds tracked by Wall St. Rank hold CRDF as of Q3 2015.

  • Fred Alger Management reported no remaining Cardiff Oncology position as of Q3 2015 after selling out during the quarter.
  • Fred Alger Management sold 918 Cardiff Oncology shares in Q3 2015, an estimated $671K.
  • Fred Alger Management first reported a position in Cardiff Oncology in Q2 2015 and held it in 1 quarter.
  • Fred Alger Management's Cardiff Oncology position peaked at $671K in Q2 2015.
  • 60 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2015.

Based on Fred Alger Management's 13F filing for Q3 2015, filed 16 Nov 2015.